Abstract
This report summarises the clinical efficacy and safety findings from clinical trials of the new anti-HER2 monoclonal antibody Herceptin(R) (trastuzumab). Data from pivotal trials indicate that trastuzumab is active when added to chemotherapy in patients with advanced metastatic breast cancer. In particular, the combination significantly prolonged the median time to disease progression, increased the overall response rate, increased the duration of response, and improved median survival time by approximately 25% compared with chemotherapy alone. Furthermore, trastuzumab is active as a single agent in women with HER2-positive metastatic breast cancer, inducing durable objective tumour responses. In total, 15% of patients who had received extensive prior treatment for metastatic disease had an objective response. The median duration of response was 9.1 months following administration of single-agent trastuzumab. Notably, 2% of patients were free of disease progression at 6 months. The safety profile of trastuzumab either given alone or in combination was favourable.
References
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Sep 1, 1993·Cancer Immunology, Immunotherapy : CII·G D LewisH M Shepard
Nov 12, 1998·Oncogene·R J PietrasD J Slamon
May 9, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C VogelS J. Stewart
Citations
Apr 2, 2013·Angiogenesis·E M ProkopiouJ J Walsh
Jun 28, 2012·Breast Cancer Research and Treatment·Aisha FasihRaymond M Reilly
Jul 10, 2008·Investigational New Drugs·Noor Al-DasooqiDorothy M Keefe
Jun 12, 2009·Journal of Clinical Immunology·Sung Hee YoonTai-Gyu Kim
Nov 27, 2008·Journal of Mammary Gland Biology and Neoplasia·Quanri Jin, Francisco J Esteva
Apr 15, 2008·Archives of Pharmacal Research·Jin Won YangKeon Wook Kang
Jan 17, 2004·Molecular Immunology·J N WangN Guo
Jun 1, 2005·Pharmacology & Therapeutics·Andreas Vogt, John S Lazo
Aug 30, 2003·American Journal of Surgery·Julian A Kim
Feb 14, 2002·Immunology Letters·Janice HuangTse Wen Chang
Jun 20, 2003·European Urology·Ivar BleumerPeter F A Mulders
Sep 16, 2003·Cancer Treatment Reviews·Roy S Herbst, Fadlo R Khuri
Dec 20, 2008·Cancer Gene Therapy·S H YoonT G Kim
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
Aug 29, 2006·Hybridoma·Mehrnaz KeyhanfarGrant W Booker
Jan 15, 2003·Annual Review of Medicine·Margaret von MehrenLouis M Weiner
Apr 23, 2011·Breast Cancer Research : BCR·Mark BarokJorma Isola
Aug 23, 2012·PloS One·Polina Sysa-ShahKathleen Gabrielson
Dec 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Z LatifJ M S Bartlett
Sep 23, 2014·Nuclear Medicine and Biology·Marek PruszynskiMichael R Zalutsky